About Us
TraXel aims to improve daily lives of people living with chronic conditions. It helps patients stay in control of their health information, make more informed decisions, and track their symptoms using data-driven AI technologies and shared decision making platforms.
TraXel was founded by a group of scientists, patients, and medical doctors to bring a new scientific approach to control and making decisions about health. Our vision is to integrate advanced AI and data-driven technologies with health information to create unmatched health insights. We will help people with chronic conditions to understand how all of the factors in their life may be impacting their conditions:
- what they eat
- what they drink
- how much sleep they are getting
- what medications they are taking
- what type of exercise they do
- what their level of stress is
- where they live
and much more!
We are interested in building a platform for individuals with chronic conditions and enable them to better receive healthcare and live better. We believe that people should stay in control of their health records so that they can stay on top of their lives and make informed health decisions. Join us now and help us help you!
Please don't hesitate to contact us.
Founders

Fay Mehr, PhD
CEO
Dr. Fay Mehr is an AI scientist, entrepreneur, and MS advocate who is passionate about improving everyday lives of people with chronic conditions. Inspired by her personal and volunteer experiences at ASOSU and MS society, she developed a great passion for helping people with chronic conditions overcome their interconnected health issues.
Dr. Mehr’ s aim, which is reflected in co-founding TraXel, is to provide novel user-friendly approaches to improve every day lives of patients, provide them with personal data-driven health recommendations, and help them track their symptoms to manage their everyday lives more efficiently. She has earned her PhD from UC San Diego, focused on machine learning methods applied in systems biology, including complex genetic networks. During her PhD, Dr. Mehr tried to model changes in gene expressions of a group of MS patients under DMT.
